@article{693a44718a0949ae8ca2ad63ad0044ed,
title = "Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update",
keywords = "Single-agent rituximab, Natural-killer-cell, Indolent lymphoma, Phase-iii, Response criteria, Plus rituximab, Advanced-stage, Open-label, Maintenance, Survival, 3121 General medicine, internal medicine and other clinical medicine",
author = "Eva Kimby and S{\"a}mi Sch{\"a}r and Pirosa, \{Maria Cristina\} and Anna Vanazzi and Mey, \{Ulrich M.\} and Daniel Rauch and Wahlin, \{Bjoern E.\} and Felicitas Hitz and Micaela Hernberg and Ann-Sofie Johansson and Brown, \{Peter de Nully\} and Hans Hagberg and Ferreri, \{Andres Jose Maria\} and Fatime Krasniqi and Voegeli, \{Mich ele\} and Urban Novak and Thilo Zander and Hanne Bersvendsen and Christoph Mamot and Walter Mingrone and Anastasios Stathis and Stefan Dirnhofer and Stefanie Hayoz and Bjorn Ostenstad and Emanuele Zucca",
year = "2025",
month = apr,
day = "8",
doi = "10.1182/bloodadvances.2024014840",
language = "English",
volume = "9",
pages = "1712--1719",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "7",
}